Repligen Corp (RGEN) is a publicly traded Healthcare sector company. As of July 15, 2026, RGEN trades at $148.62 with a market cap of $8.17B and a P/E ratio of 158.91. RGEN moved +0.34% today. Year to date, RGEN is -10.21%; over the trailing twelve months it is +21.26%. Its 52-week range spans $100.99 to $182.52. Analyst consensus is strong buy with an average price target of $164.92. Rallies surfaces RGEN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks politician and congressional stock disclosures for RGEN, including purchases, sales, transaction dates, owners, and reported trade amounts when available.
| Metric | Value |
|---|---|
| Price | $148.62 |
| Market Cap | $8.17B |
| P/E Ratio | 158.91 |
| EPS | $0.92 |
| Dividend Yield | 0.00% |
| 52-Week High | $182.52 |
| 52-Week Low | $100.99 |
| Volume | 77.39K |
| Avg Volume | 0 |
| Revenue (TTM) | $763.34M |
| Net Income | $51.40M |
| Gross Margin | 52.90% |
15 analysts cover RGEN: 0 strong buy, 12 buy, 3 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $164.92.